NEWS RELEASES

BOSTON, May 05, 2022 (GLOBE NEWSWIRE) -- PepGen, Inc., a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the pricing of its initial public

Initiation of Phase 1 Study Marks PepGen’s Transition to a Clinical Stage Company    This Phase 1 Healthy Normal Volunteer (HNV) Study will Evaluate Safety and Tolerability as the Primary Objective, and will Begin to Evaluate the Delivery and Target Engagement of PGN-EDO51 to Enable Subsequent

Dr. Mellion brings deep experience in neuromuscular disease research and treatment as a biopharma executive, researcher and physician BOSTON, April 5, 2022 – PepGen, Inc., a company developing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe

BOSTON, March 30, 2022 – PepGen, Inc., advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurologic diseases, today announced that it has appointed Jennifer Cormier as Senior Vice President, Clinical Operations and Dr.

Updates on preclinical data and the clinical development plan will be presented at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference BOSTON, March 15, 2022 – PepGen Inc., a company advancing the next generation of oligonucleotide therapies for neuromuscular and neurologic

Keating brings strong experience as a life science executive and Board member BOSTON, January 19, 2022 –  PepGen, Inc. , a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced that it has appointed Laurie Keating as Chair of the